semaj83/ctmatch_classification huggingface dataset:
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetic Foot Varicose Ulcer Pressure Ulcer Patients who are at least 18 years of age Males and females (provided they are not pregnant or, if of reproductive age, are using contraception) Patients with a venous stasis, diabetic foot or decubitus reference ulcer located between the tibia and foot Patients undergoing surgical debridement of their reference ulcer in the operating room (OR) Patients undergoing their first surgical debridement of the reference ulcer Patients suitable for debridement of their reference ulcer with both and conventional debridement techniques Patients who are able to understand the evaluation and are willing and able to provide written consent to participate in the evaluation  Patients with clinical signs of infection in the reference ulcer (e.g. purulence and / or odour) Patients with haemophilia Patients who have been treated with topical steroids, systemic immunosuppressants (including corticosteroids), anticoagulants or cytotoxic chemotherapy in the last 30 days, or who are anticipated to require such medications during the course of the study Patients known to have Acquired Immunodeficiency Syndrome (AIDS) or known to be infected with Human Immunodeficiency Virus (HIV) Patients who suffer from acute or chronic bacterial, viral or fungal skin diseases that would interfere with wound healing Patients with a known history of poor compliance with medical treatment Patients who have participated in this evaluation previously or are currently participating in another clinical study
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus Chronic Ulcers of the Lower Limb Age > 18 years Type 1 or 2 Diabetes Mellitus Wagner grading of foot lesions 3 or 4 on lower limb not healing for 4 weeks  Impending urgent amputation due to ongoing or exacerbated infection Exposed calcaneus bone with no prospect of weight bearing potential even if defect has been healed Dialysis-dependent renal failure Any of the following medical conditions which preclude safe treatment in a monoplace chamber: clinical depression; severe dementia; claustrophobia; seizure disorder; active asthma; severe chronic obstructive pulmonary disease; previous thoracic surgery; previous spontaneous or trauma induced pneumothorax; history of severe congestive heart failure with left ventricular ejection fraction less than 20%; unstable angina; chronic sinusitis; chronic or acute otitis media or major ear drum trauma; severe kyphoscoliosis; arthritis; or morbid obesity History of chemotherapy with use of Bleomycin Participation in another investigative drug or device trial currently or within the last 30 days Current candidates for vascular surgery, angioplasty or stenting Major large vessel disease Undergone vascular surgery or angioplasty within the last 3 months Women who are currently pregnant or are breast feeding or women of childbearing potential who are not currently taking adequate birth control
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Type 1 diabetes Type 2 diabetes Candidates of use of a basal insulin as part of their diabetes regimen  Unwilling to adhere to therapy or follow up Pregnancy
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes At least 2 dispensings for oral medications used to treat diabetes and dyslipidemia in the last 18 month At least one laboratory result for both glycated hemoglobin and LDL-cholesterol in the last 6 months Average HbA1c ≥ 7% OR an average LDL ≥ 100 mg/d Continuous health plan enrollment currently and in the previous calendar year with no more than a 1 month lapse of coverage, and benefits that both medical and pharmacy coverage  Patients who have been institutionalized in a nursing home or in a long-term care facility for more than 3 months in the preceding 18 month period Participation in a disease management program
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Corneal Ulcer The corneal ulcer patients who are diagnosed by ophthalmologist and have 2 of 3 in these following features corneal epithelial defect with stromal infiltration reaction in anterior chamber positive for bacteria or fungus The patients have to receive subconjunctival antibiotic injection twice at least The patients must be informed consent  The patients who have history of allergy of local anesthetics, antibiotics or antifungal drugs The patients who administered NSAIDs or weak opioids within 24 hours prior to subconjunctival antibiotic/antifungal injection Unable to cooperate with the treatment Pregnant women
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Leg Ulcers • Patients over 18 who have given written informed consent Patients with a venous or predominantly venous leg ulcer (ankle-brachial index > 0.8) that is between 2 cm and 13 cm in all directions Patients with a moderately or severely exudating leg ulcer in the phase of debridement or formation of granulation tissue Patients with a leg ulcer that is not healing properly despite suitable and well-conducted local treatment in the four weeks prior to Patients with a leg ulcer that has been treated with appropriate compression in the four weeks prior to Patients who are available for monitoring for at least 10 weeks  • Patients whose leg ulcers are clinically infected (including erysipelas and cellulitis of the skin around the ulcer) requiring systemic antibiotic treatment Patients who have undergone surgery on the saphenous trunk within the two months prior to Patients whose leg ulcer being considered for the study has been treated with local antibiotics or antiseptics incl. dressings containing antibiotics or antiseptics in the four weeks prior to Patients who have been taking systemic antibiotics in the two weeks prior to Patients who have been taking systemic corticoids or cytostatics within the three months prior to Patients with unbalanced diabetes at the discretion of the investigator Patients with a known allergy to one of the components in Biatain Argent® or Biatain Patients who are already taking part in another clinical study Patients who are pregnant or breastfeeding
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Brain Injury Sequelae Stroke Anoxia Trauma Subject has had a brain injury at least 12 months prior to study enrollment Subject is at least 18 years old Etiology of brain injury: Stroke, anoxia, and trauma Must be able to equalize ears, or have tympanostomy tubes Willingness to complete outcome measures and complies with the research protocols Commitment to pay the hospital for hyperbaric oxygen  Glasgow Coma Scores less than 13 at the time of hyperbaric oxygen evaluation Poorly controlled seizures(ie:>1 generalized seizure in past 3 months despite appropriate anticonvulsant therapy). Pharmacologically-controlled seizures or focal seizures are not an to participate Inability to participate in outcome assessments (eg: blindness, quadraplegia) Claustrophobia (unwillingness or inability to enter the hyperbaric chamber) Inability to equalize ears. The patient could elect to have bilateral tympanostomy tubes Inability to protect airway, and or requiring frequent suctioning Patients requiring tracheostomy will be ineligible due to limitations in autoinflation of the middle ear space and difficulty to perform airway suctioning in the single-person chamber Pregnancy (beta HCG will be assayed in women who could be pregnant prior to enrollment) Severe psychiatric disorders such as schizophrenia and bi-polar disease. We appreciate that psychiatric problems such as depression and anxiety may follow brain injuries so we would not patients based on brain-injury induced psychiatric disorders, but will patients with severe pre-injury psychiatric disorders Patients taking lithium (due to the possibility of concomitant toxic side effects with hyperbaric oxygen therapy, specifically hyperexcitability)
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetic Foot Ulcer In-patient or out-patient patients diagnosed with diabetic foot ulcers Gangrene or ulceration occurred more than 3 weeks Over 18 years of age Gender-open The type of diabetes (type 1 or type 2) open Patients receive a written informed consent to participate in the trial  Serious complications of heart, liver, lung, kidney damage Malignant tumors Allergy for Chinese medicine used Pregnant women and breast-feeding women
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Trigeminal Neuralgia Pain Age 18-70 Primary TN patient (MRI examination support diagnosis) Suffering from this pain for at least 3 months VAS﹥40mm Patient can assess pain intensity correctly  Undergone surgery for TN(including nerve injections) within the last year Oral medicine change within the last week With other diseases of nervous system
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 20.0-75.0,  CERVICAL NEOPLASMS Histologically confirmed cervical cancer Clinical stage from 2b to 4a Equal to or younger than 75 Gog performance status 0 Anc > 1500/mm3 and platelet > 100000/mm3 and hemoglobin > 10 g/dl Serum creatinine < 2.0 AST, ALT < 3 * upper normal level and serum bilirubin < 1.5 mg/dl Expected survival equal to or longer than 6 months Who agreed to participate in this study  History of chemotherapy or radiation to abdomen or pelvis History of other cancers Pleural or pericardial effusion, ascites causing respiratory difficulties equal to or worse than NCI CTCAE grade 2 History of allergy or hypersensitivity reaction to platinum History of atrial or ventricular arrhythmia, or congestive heart failure Uncontrolled diabetes, hypertension, or ischemic heart disease Myocardial infarction within 6 months Sepsis or severe infection Pregnant women An unapproved therapy within 30 days before enrollment
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  At-risk Drinking Type 2 Diabetes years or older have Type 2 diabetes report at-risk drinking in past month report poor diabetes treatment adherence  current alcohol dependence or current psychoactive substance abuse or dependence (excluding nicotine) currently psychotic unable to provide the name and contact information for a significant other to corroborate self-report unable to provide the name and contact information for two people who could serve as locators, do not have access to a telephone
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Autologous Transplantation Diabetic Foot Age from 40 to 70 years Type 2 diabetic patients bilateral critical limb ischemia(ABI from 0.30 to 0.60) at least with one foot ulcer  dry gangrene above the ankle or moist gangrene malignant tumor severe coronary,cerebral and renal vascular disease
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  MARTORELL'S ULCER Hypertensive Leg Ulcer Necrotic Angiodermatitis patients 18 years of age or older, able to give informed consent and to follow the treatment procedure target ulcer area between 1 and 30 cm2 consecutive patients presenting with one or more leg ulcers diagnosed as hypertensive ulcers presence of an arterial hypertension, according to the WHO treated or not; and/or presence of a diabetes treated by oral agent, insulin or diet absence of clinical signs of chronic venous insufficiency: skin hyperpigmentation, lipodermatosclerosis absence of significant peripheral arterial occlusive disease: presence of peripheral pulses or ankle brachial index ≥0.8 absence of clinical sign of arterial insufficiency: intermittent claudication, resting pain superficial spreading necrotic ulcer presence of spontaneous pain presence of a red purpuric margin  pregnancy allergy to hydrogel or to becaplermin gel uncontrolled or evolving systemic disease: cardiac or renal failure, hepatic insufficiency, malignant disease, thrombotic disease, vasculitis or other connective tissue disorder presence of a cryoglobulinemia serum creatinine concentration greater than 200µmol/L or uncontrolled diabetes (fasting blood glucose > 2,5 g/L under treatment) concomitant treatment by bone, joint or tendon (except for achilles tendon) exposition in the wound systemic treatment with corticosteroid agents or cytotoxic drugs in the past 3 months before
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Wounds Subject must have evidence of a full-thickness cutaneous wound of at least 30 days duration Subject must be at least 18 years of age Subject must have a minimum life expectancy of at least 1 year to be determined by the Investigator The study ulcer must be from 1 cm2 to 20 cm2 in size The study ulcer must have been present for at least 30 days at study Day -7 The subject's Glycosylated hemoglobin (HbA1C) must be equal to or less than 10.0% for subjects with diagnosed diabetes at study Day 0 The subject, legal guardian or authorized representative must have understood, signed and dated the IRB approved informed consent form The subject must be available for evaluation on a weekly basis for the twelve (12) weeks of the study. Visits at Week 13 and Week 14 are required for initial wound healing, which is achieved in study Week 11 or 12. The Investigator will evaluate both groups at Week 16. Subjects must be available for evaluation at Week 16 The subject's TCpO2 must be equal to or greater than 25 mm of mercury in the periwound area and ABI greater than 0.7  Subject whose ulcer has healed 30% or greater from the evaluation Study day -7 to the post-debridement Study Day 0 as determined by wound measurements using ARANZ Silhouette A history of alcohol or substance abuse, within the previous year, which could, or in the judgment of the Investigator, would interfere with study compliance or protocol requirements Participation in clinical trials evaluating investigational pharmaceuticals, biologics or devices within 30 days of admission to the study Subject with a history of receiving any of the following within the last 30 days: systemic corticosteroids exceeding a total daily dose of 20mg, immunosuppressive agents, radiation therapy or chemotherapy. Anticipated use of the above during the study period will also a subject from entry into the study. Topical and inhaled corticosteroids are not prohibited Subjects with medical comorbidities known to affect wound healing such as end stage renal disease, severe hepatic insufficiency, vasculitis, and HIV will be excluded from this study
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Diabetes Neuropathic Foot diagnosed as having Type 1 or 2 diabetes mellitus, (recorded within the case notes and confirmed by participant) diagnosed with diabetic peripheral neuropathy palpable or biphasic pulses intact from lower limb vascular or neuropathic ulceration, scoring Grade 0 on the Wagner classification for foot ulcer able to walk a minimum of 10 metres unaided willing to comply with the requirements of the study  presented with current or recently healed ulceration less than 6 months prior to study enrolment severe fixed mid-foot or rearfoot deformity e.g. charcot joint, unsuitable for prefabricated insoles and non bespoke footwear history of major bone or joint surgery of the lower limb including major amputation unable to comprehend simple instructions and comply with the study protocols and procedures
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Diabetic Foot The presence of neuropathic plantar ulcer with an area graded IA according to the Texas University classification, AND The presence of peripheral neuropathy. Peripheral neuropathy was diagnosed based on insensitivity to a 10-g Semmes-Weinstein monofilament in more than 6 out of 9 areas of the foot and by a vibration perception threshold measured by biothesiometer (Neurothesiometer SLS, Nottingham, UK) at the malleolus > 25 volts  Presence of an ankle-brachial pressure index (ABI) < 0.9 and/or transcutaneous oxygen tension (TcPO2) < 50 mmHg tested on the dorsum of the foot Presence of clinical signs of infection, including edema, erythema, increased local skin temperature, or drainage The probe-to-bone maneuver was required to be negative Tthe standard X-ray examination of the foot was required to be negative for osteomyelitis Use of steroids or cytostatic drugs Presence of sensory, motor, or visual problems that could impair functional autonomy Active ulcer on the contralateral foot Previous major amputation of the contralateral limb Previous or current deep venous leg thrombosis, OR Mental disorders interfering with patient compliance